Prostate Cancer

In 2 separate studies, apalutamide (Erleada) and enzalutamide (Xtandi) reduced the risk for metastasis and prolonged metastasis-­free survival in patients with nonmetastatic castrate-resistant prostate cancer (CRPC), according to the results of 2 clinical trials presented at the 2018 Genitourinary Cancers Symposium.

For patients with metastatic hormone-naïve prostate cancer, practice-changing results from the LATITUDE clinical trial showed that the use of abiraterone plus low-dose prednisone in addition to androgen-deprivation therapy (ADT) delayed disease progression by an average of 18 months, and reduced the risk for death by 38%, when compared with ADT alone.

Adding abiraterone to standard initial treatment that includes androgen-deprivation therapy (ADT) increased survival and reduced mortality risk by 37% over 3 years versus standard of care in the STAMPEDE study of men with locally advanced or metastatic prostate cancer.

Enzalutamide did not increase the rate of seizures in men with metastatic castration-resistant prostate cancer (mCRPC) who had potential risk factors for seizure, according to results of the phase 4 UPWARD trial.

Results 1 - 4 of 4